CERTARA

CODEX Clinical Outcomes Databases

Relapsed and Refractory Multiple Myeloma (RRMM)

Curated clinical trial data for earlier, confident decisions

Certara's Clinical Trial Outcomes Database (CODEX) is an expertly curated database of clinical trial data for marketed and pipeline drugs, covering 8 therapeutic areas and 70+ indications. It includes structured and unstructured data that can be downloaded and integrated with internal datasets to support modeling and simulation, enabling earlier, more confident drug development decisions.

With CODEX, you can:

Identify the right trial populations
analyze clinical data to identify target populations for new studies.

Improve study design
refine sample size calculations to reduce costs and increase success rates.

Strengthen regulatory strategy
review integrated summaries of safety and efficacy (ISS/ISE) for similar products to inform regulatory approval strategies.

Demonstrate commercial viability
run economic models to generate additional data points that can be used to demonstrate value to payers and in competitive pricing assessments.

Model-based meta-analysis (MBMA)

MBMA leverages CODEX databases and pharmacology models to increase development productivity, quantitatively inform portfolio decisions, and improve clinical trial success. It optimizes trial design, including timing, endpoints, and dosing, as well as competitive landscape assessment. MBMA also bridges across studies, allowing comparison of treatments and patient populations that may not have been evaluated within the same trial.

~414 studies

Key Response to treatment & Survival Endpoints (Complete, Partial & Stable responses, ORR , OS & PFS)

~43,687 patients

All systemic or novel pharmacological treatments with primary focus on chemo & targeted therapy

~116,004

Longitudinal Data Points – Format available in Excel and CODEX (Clinical Outcomes Database Explorer)

CERTARA

A comprehensive repository of RRMM clinical outcomes

The CODEX Relapsed and Refractory Multiple Myeloma (RRMM) Database provides utility across the drug development continuum to inform critical decisions that determine not only a drug's successful performance during a trial, but also a drug's profile within a competitive landscape. The RRMM Database highlighted here is curated to document clinical efficacy and safety information from all prospective clinical trials in Relapsed and Refractory Multiple Myeloma patients. Trials found in this database also include washout designs and add on designs.

Treatment	Class	Studies
pomalidomide+dexamethasone	immunomodulator+steroid	23
lenalidomide+dexamethasone	immunomodulator+steroid	13
thalidomide+dexamethasone	immunomodulator+steroid	12
bortezomib	proteasome inhibitor	11
thalidomide	immunomodulator	10
bortezomib sc+dexamethasone	proteasome inhibitor+steroid	9
carfilzomib+dexamethasone	proteasome inhibitor+steroid	8
daratumumab	anti-CD38	8
bortezomib+dexamethasone	proteasome inhibitor+steroid	7
carfilzomib	proteasome inhibitor	7
daratumumab+bortezomib sc+dexamethasone	anti-CD38+proteasome inhibitor+steroid inhibitor+steroid	6

Table 1. The top 11 drugs in the CODEX RRMM database



Figure 1. Snapshot of select treatments; OS time course

CERTARA



Figure 2. PFS time course for trials with bortezomib

About Certara

Certara accelerates medicines using proprietary biosimulation software, technology and services to transform traditional drug discovery and development. Its clients include more than 2,600 biopharmaceutical companies, academic institutions and regulatory agencies across 70 countries.
Visit certara.com |

CERTARA